Anti-Müllerian hormone receptor: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
m (Replace magic links with templates per local RfC and MediaWiki RfC)
 
imported>JCW-CleanerBot
m (→‎Pathology: task, replaced: Clinical Cancer Research : an Official Journal of the American Association for Cancer Research → Clinical Cancer Research)
 
Line 23: Line 23:
The anti-Müllerian hormone receptor (Müllerian Inhibiting Substance Type II Receptor) can be responsible for [[persistent Müllerian duct syndrome]].
The anti-Müllerian hormone receptor (Müllerian Inhibiting Substance Type II Receptor) can be responsible for [[persistent Müllerian duct syndrome]].


Müllerian inhibiting substance type II receptor (MISIIR), also known as the Anti-Müllerian Hormone Receptor, is expressed by [[ovarian cancer|ovarian]], [[breast cancer|breast]], and [[prostate cancer]]s and these cancer cells have been reported to [[apoptosis|apoptose]] in response to exposure to the Müllerian inhibiting substance (MIS).
Müllerian inhibiting substance type II receptor (MISIIR), also known as the Anti-Müllerian Hormone Receptor, is expressed by [[ovarian cancer|ovarian]], [[breast cancer|breast]], and [[prostate cancer]]s and these cancer cells have been reported to [[apoptosis|apoptose]] in response to exposure to the Müllerian inhibiting substance (MIS).<ref name="pmid10589763">{{cite journal | vauthors = Masiakos PT, MacLaughlin DT, Maheswaran S, Teixeira J, Fuller AF, Shah PC, Kehas DJ, Kenneally MK, Dombkowski DM, Ha TU, Preffer FI, Donahoe PK | title = Human ovarian cancer, cell lines, and primary ascites cells express the human Mullerian inhibiting substance (MIS) type II receptor, bind, and are responsive to MIS | journal = Clinical Cancer Research | volume = 5 | issue = 11 | pages = 3488–99 | date = November 1999 | pmid = 10589763 | doi = }}</ref>
<ref>Masiakos PT, et al. Human ovarian cancer, cell lines, and primary ascites cells express the human Müllerian inhibiting substance (MIS) Type II Receptor, bind, and are responsive to MIS. Clin Cancer Res 1999;5:3488-99</ref>


[[Antibody|Antibodies]] have been developed that specifically target MISIIR and may be useful as vehicles for drugs and toxins for targeted [[cancer therapy]].<ref>Yuan QA, Robinson MK, Simmons HH, Russeva M, Adams GP. Isolation of anti-MISIIR scFv molecules from a phage display library by cell sorter biopanning. Cancer Immunol Immunother. 2008, 57(3):367-78. {{PMID|17676323}}</ref><ref>Yuan QA, Simmons HH, Robinson MK, Russeva M, Marasco WA, Adams GP.  Development of engineered antibodies specific for the Müllerian inhibiting substance type II receptor: a promising candidate for targeted therapy of ovarian cancer. Mol Cancer Ther. 2006, 5(8):2096-105. {{PMID|16928831}}</ref><ref>Salhi I, Cambon-Roques S, Lamarre I, Laune D, Molina F, Pugnière M, Pourquier D, Gutowski M, Picard JY, Xavier F, Pèlegrin A, Navarro-Teulon I.  Salhi I, Cambon-Roques S, Lamarre I, Laune D, Molina F, Pugnière M, Pourquier D, Gutowski M, Picard JY, Xavier F, Pèlegrin A, Navarro-Teulon I. The anti-Müllerian hormone type II receptor: insights into the binding domains recognized by a monoclonal antibody and the natural ligand. Biochem J. 2004 May 1;379(Pt 3):785-93.  {{PMID|14750901}}</ref>
[[Antibody|Antibodies]] have been developed that specifically target MISIIR and may be useful as vehicles for drugs and toxins for targeted [[cancer therapy]].<ref name="pmid17676323">{{cite journal | vauthors = Yuan QA, Robinson MK, Simmons HH, Russeva M, Adams GP | title = Isolation of anti-MISIIR scFv molecules from a phage display library by cell sorter biopanning | journal = Cancer Immunology, Immunotherapy : CII | volume = 57 | issue = 3 | pages = 367–78 | date = March 2008 | pmid = 17676323 | doi = 10.1007/s00262-007-0376-2 }}</ref><ref name="pmid16928831">{{cite journal | vauthors = Yuan QA, Simmons HH, Robinson MK, Russeva M, Marasco WA, Adams GP | title = Development of engineered antibodies specific for the Müllerian inhibiting substance type II receptor: a promising candidate for targeted therapy of ovarian cancer | journal = Molecular Cancer Therapeutics | volume = 5 | issue = 8 | pages = 2096–105 | date = August 2006 | pmid = 16928831 | doi = 10.1158/1535-7163.MCT-06-0115 }}</ref><ref name="pmid14750901">{{cite journal | vauthors = Salhi I, Cambon-Roques S, Lamarre I, Laune D, Molina F, Pugnière M, Pourquier D, Gutowski M, Picard JY, Xavier F, Pèlegrin A, Navarro-Teulon I | title = The anti-Müllerian hormone type II receptor: insights into the binding domains recognized by a monoclonal antibody and the natural ligand | journal = The Biochemical Journal | volume = 379 | issue = Pt 3 | pages = 785–93 | date = May 2004 | pmid = 14750901 | pmc = 1224123 | doi = 10.1042/BJ20031961 }}</ref>


==References==
==References==

Latest revision as of 16:53, 23 August 2018

Anti-Müllerian hormone receptor, type II
Identifiers
SymbolAMHR2
Entrez269
HUGO465
OMIM600956
RefSeqNM_020547
UniProtQ16671
Other data
LocusChr. 12 q13

Anti-Müllerian hormone receptor is a receptor for anti-Müllerian hormone.

Pathology

The anti-Müllerian hormone receptor (Müllerian Inhibiting Substance Type II Receptor) can be responsible for persistent Müllerian duct syndrome.

Müllerian inhibiting substance type II receptor (MISIIR), also known as the Anti-Müllerian Hormone Receptor, is expressed by ovarian, breast, and prostate cancers and these cancer cells have been reported to apoptose in response to exposure to the Müllerian inhibiting substance (MIS).[1]

Antibodies have been developed that specifically target MISIIR and may be useful as vehicles for drugs and toxins for targeted cancer therapy.[2][3][4]

References

  1. ↑ Masiakos PT, MacLaughlin DT, Maheswaran S, Teixeira J, Fuller AF, Shah PC, Kehas DJ, Kenneally MK, Dombkowski DM, Ha TU, Preffer FI, Donahoe PK (November 1999). "Human ovarian cancer, cell lines, and primary ascites cells express the human Mullerian inhibiting substance (MIS) type II receptor, bind, and are responsive to MIS". Clinical Cancer Research. 5 (11): 3488–99. PMID 10589763.
  2. ↑ Yuan QA, Robinson MK, Simmons HH, Russeva M, Adams GP (March 2008). "Isolation of anti-MISIIR scFv molecules from a phage display library by cell sorter biopanning". Cancer Immunology, Immunotherapy : CII. 57 (3): 367–78. doi:10.1007/s00262-007-0376-2. PMID 17676323.
  3. ↑ Yuan QA, Simmons HH, Robinson MK, Russeva M, Marasco WA, Adams GP (August 2006). "Development of engineered antibodies specific for the Müllerian inhibiting substance type II receptor: a promising candidate for targeted therapy of ovarian cancer". Molecular Cancer Therapeutics. 5 (8): 2096–105. doi:10.1158/1535-7163.MCT-06-0115. PMID 16928831.
  4. ↑ Salhi I, Cambon-Roques S, Lamarre I, Laune D, Molina F, Pugnière M, Pourquier D, Gutowski M, Picard JY, Xavier F, Pèlegrin A, Navarro-Teulon I (May 2004). "The anti-Müllerian hormone type II receptor: insights into the binding domains recognized by a monoclonal antibody and the natural ligand". The Biochemical Journal. 379 (Pt 3): 785–93. doi:10.1042/BJ20031961. PMC 1224123. PMID 14750901.

External links


Retrieved from "https://www.wikidoc.org/index.php?title=Anti-Müllerian_hormone_receptor&oldid=1528385"